Skip to main content
. Author manuscript; available in PMC: 2018 Dec 28.
Published in final edited form as: Nat Rev Microbiol. 2012 Sep 10;10(10):681–692. doi: 10.1038/nrmicro2872

Table 1 |.

Characteristics of commercial human papillomavirus virus-like particle-based vaccines

Cervarix Gardasil
Manufacturer GlaxoSmithKline Biologicals Merck
VLP types included HPV16 and HPV18 HPV6, HPV11, HPV16 and HPV18
Dose of L1 protein 20 μg from both types 20 μg (HPV6),40 μg (HPV11),40 μg (HPV16) and 20 μg (HPV18)
Producer cells Trichoplusia ni (Hi 5) cell line infected with L1-recombinant baculovirus Saccharomyces cerevisiae expressing L1
Adjuvant 500 μg aluminium hydroxide and 50 μg 3–0-deacylated-4′-monophosphoryl lipid A 225 μg aluminium hydroxyphosphate sulphate
Injection schedule 0, 1 and 6 months 0, 2 and 6 months

HPV, human papillomavirus; VLP, virus-like particle.